Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2024

Genmab — April 2024

Planlagt Fastgjort Låst Flyttet Genmab
759 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #713

    Genmab og partner henter fuld amerikansk godkendelse til livmoderhalskræftmiddel https://www.proinvestor.com/investornyt/1152227/genmab-og-partner-henter-fuld-amerikansk-godkendelse-til-livmoderhalskraeftmiddel

    1 Reply Last reply
    0
    • T Offline
      T Offline
      transalp
      wrote on sidst redigeret af
      #714

      Go morgen.. 🙂

      1 Reply Last reply
      0
      • royalR Offline
        royalR Offline
        royal
        wrote on sidst redigeret af
        #715

        Spændende hvad det koster på kursen. 🙂

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #716

          Argh, det er vel ikke så stor en overraskelse, at det slår bunden ud af aktien;-)

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #717

            nicely on time, PDUFA goal date was May 9

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #718

              Dejligt med endnu en god nyhed 🙂

              1 Reply Last reply
              0
              • V Offline
                V Offline
                Vitus
                wrote on sidst redigeret af
                #719

                Betyder det noget…..

                1 Reply Last reply
                0
                • W Offline
                  W Offline
                  w
                  wrote on sidst redigeret af
                  #720

                  Alt er indregnet;)

                  1 Reply Last reply
                  0
                  • V Offline
                    V Offline
                    Vitus
                    wrote on sidst redigeret af
                    #721

                    Vor herre bev……

                    1 Reply Last reply
                    0
                    • royalR Offline
                      royalR Offline
                      royal
                      wrote on sidst redigeret af
                      #722

                      Lige før man håber på et dårligt Q1 på torsdag.

                      1 Reply Last reply
                      0
                      • W Offline
                        W Offline
                        w
                        wrote on sidst redigeret af
                        #723

                        Komplet uforståeligt at den kan falde på en godkendelse, der iøvrigt kom før tid

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #724

                          This full approval is the minimum requirement to continue with Tivdak and therefore an important step. It will depend on how much new owner Pfizer sees in the drug, but the EMA application and current conversations with regulators to continue also in head and neck cancer bode well for now.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #725

                            Tivdak seems to go a little bit under the radar, but 'According to GlobalData’s patient-based forecast, Tivdak is forecast to generate sales of $1.4bn in the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada) by 2030'

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #726

                              Link Preview Image
                              Highlights from ESMO 2023: Antibody-drug conjugates and bispecific T-cell engagers

                              At ESMO 2023, much of the focus was on new data for antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs)

                              favicon

                              Clinical Trials Arena (www.clinicaltrialsarena.com)

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #727

                                i am sure we will still all be here in 2030 to see if that comes true, whilst complaining about the share price 😉

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  Bullish
                                  wrote on sidst redigeret af
                                  #728

                                  OB og Genmab har noget til fælles for tiden..

                                  1 Reply Last reply
                                  0
                                  • R Offline
                                    R Offline
                                    Riis7
                                    wrote on sidst redigeret af
                                    #729

                                    Og fcm:-)

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      GeorgeBest
                                      wrote on sidst redigeret af
                                      #730

                                      Thanks E L 09:48. Can you also see what’s the forecast for epcoritamab is by 2030?

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #731

                                        'GlobalData’s consensus forecast forecasts that Epkinly will achieve blockbuster status by 2027, with global sales expected to exceed $1.9bn by 2029.' from may last year https://www.clinicaltrialsarena.com/analyst-comment/abbvie-genmab-epkinly-dlbcl/?cf-view

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #732

                                          Due to Epkinly's tremendous efficacy, analysts at SVB Securities think that the drug could reach peak annual sales of $3 billion in the U.S. https://www.nasdaq.com/articles/could-this-new-drug-be-a-blockbuster-for-these-2-pharma-collaborators

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper